Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q3 2023 · 10-Q
Revenue$127.32M$127.32M−2.8% vs Q3 2022 Net Income-$49.49M-$49.49MN/M vs Q3 2022 EPS Diluted-$0.46-$0.46N/M vs Q3 2022 Gross Profit$95,229,000−5.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow-$19,314,000N/M Free Cash Flowderived-$26,567,000N/M Margins · derivedGross margin74.8%−2.5 pt vs Q3 2022
Operating margin-45.7%−27.0 pt vs Q3 2022
Net margin-38.9%−18.6 pt vs Q3 2022
ended Sep 30, 2023 · filed Oct 26, 2023 · 26 d after period end